Lobbying Filing Details

Total Spending

$940,000

Activities

4

Lobbyists

3

Gov't Entities

8

Filing Information
Filing UUID:
74f99ef8-fe4f-48e5-b525-bc8334b98172
Type:
Q4 - 4th Quarter - Report
Period:
2014 - 4th Quarter (Oct 1 - Dec 31)
Date Posted:
January 20, 2015 at 10:42 PM
Income:
$0
Expenses:
$940,000
Expense Method:
Method A - Reporting amounts using LDA definitions only
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Debbie Garza, Divisional Vice President Government and Community Relations
Registrant
WALGREEN COMPANY

Retail Pharmacy

WASHINGTON, District of Columbia
Client
WALGREEN COMPANY
District of Columbia, United States of America
Lobbying Activities (4)
Activity 1
Alcohol and Drug Abuse

S. 2862 - "Regulatory Transparency, Patient Access and Effective Drug Enforement Act of 2014," all provisions related to changes to the registration process under the Controlled Substances Act and the report to Congress on the effects of law enforcement activities on patient access to medications.H.R. 4709 - the "Ensuring Patient Access and Effective Drug Enforcement Act of 2014," all provisions related to changes to the registration process under the Controlled Substances Act and the report to Congress on the effects of law enforcement activities on patient access to medications.

Lobbyists (3)
  • DEBBIE GARZA
  • ALETHIA JACKSON
  • MR. EDWARD KALETA III
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Medicare/Medicaid

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.

Lobbyists (3)
  • DEBBIE GARZA
  • ALETHIA JACKSON
  • MR. EDWARD KALETA III
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
Pharmacy

H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communitites, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

Lobbyists (3)
  • DEBBIE GARZA
  • ALETHIA JACKSON
  • MR. EDWARD KALETA III
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 4
Taxation/Internal Revenue Code

Issues related to United States corporate tax reform - no specific legislation.S. 336 - the "Marketplace Fairness Act," all provisions regarding authorizing each state under the Streamlined Sales and Use Tax Agreement (the multistate agreement for the administration and collection of sales and use taxes adopted on November 12, 2002) to require all sellers not qualifying for a small-seller exception (applicable to sellers with annual gross receipts in total U.S. remote sales not exceeding $1 million) to collect and remit sales and use taxes.

Lobbyists (3)
  • DEBBIE GARZA
  • ALETHIA JACKSON
  • MR. EDWARD KALETA III
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 9, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.